Amondys 45 (Casimersen)

Amondys 45 (Casimersen)

Amondys 45

Casimersen

100 mg/2 mL in a Single-Dose Vial

Sarepta Therapeutics, Inc.

Medical Use

Amondys 45 is an antisense oligonucleotide designed to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene that allows for exon 45 skipping.

Dosage Recommendations:

  • Standard Dose: Administer 30 mg per kilogram of body weight once a week.
  • Administration: Infuse intravenously over 35 to 60 minutes using an in-line 0.2 micron filter.

If a dose of Amondys 45 (Casimersen Injection) is missed, it should be administered as soon as possible after the scheduled time.